Physician profile
Kirsten Risley
NPI 1184020216
$3,263.31
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,410 · 2022: $1,748 · 2023: $15.64 · 2024: $90.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,443.20 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $688.74 | 2021-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $287.95 | 2021-2022 | |
| Celgene Corporation | $258.84 | 2021-2022 | |
| Janssen Biotech, INC. | $240.24 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $114.27 | 2021-2022 | |
| Gilead Sciences, INC. | $62.93 | 2021-2022 | |
| Pfizer INC. | $58.31 | 2021-2022 | |
| Qol Medical, LLC | $31.83 | 2021 | |
| Intercept Pharmaceuticals, INC. | $26.69 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.34 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.06 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $15.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirsten Risley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.